The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 1, 2013, Pages 275-284

  Mitra, Aninda ^a   Sasikumar, Kotagiri ^a   Parthasaradhi, B V V ^a   Radha, Vegesna ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

Abl, Abelson; BCR, break point cluster gene; CML, chronic myelogenous leukemia; PTP, protein tyrosine phosphatase; TCPTP, T cell PTP

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; DEPHOSPHORYLATION; HUMAN; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCR;

EID: 84869101198     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.10.014     Document Type: Article

References (51)

1. Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci. Signal. 2010, 3. re6.
2. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 BCR/Abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
3. Chen Y., Peng C., Li D., Li S. Molecular and cellular bases of chronic myeloid leukemia. Protein Cell 2010, 1:124-132.
4. Smith J.M., Mayer B.J. Abl: mechanisms of regulation and activation. Front. Biosci. 2002, 7:d31-d42.
5. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 2000, 275:35631-35637.
6. Wang J.Y. Controlling Abl: auto-inhibition and co-inhibition?. Nat. Cell Biol. 2004, 6:3-7.
7. de Klein A., van Kessel A.G., Grosveld G., Bartram C.R., Hagemeijer A., Bootsma D., Spurr N.K., Heisterkamp N., Groffen J., Stephenson J.R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300:765-767.
8. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000, 289:1938-1942.
9. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 2004, 91:1-30.
10. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297.
11. LaMontagne K.R., Flint A.J., Franza B.R., Pandergast A.M., Tonks N.K. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 BCR-Abl in vivo. Mol. Cell. Biol. 1998, 18:2965-2975.
12. Bruecher-Encke B., Griffin J.D., Neel B.G., Lorenz U. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia 2001, 15:1424-1432.
13. Della Peruta M., Martinelli G., Moratti E., Pintani D., Vezzalini M., Mafficini A., Grafone T., Iacobucci I., Soverini S., Murineddu M., Vinante F., Tecchio C., Piras G., Gabbas A., Monne M., Sorio C. Protein tyrosine phosphatase receptor type gamma is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res. 2010, 70:8896-8906.
14. Motiwala T., Majumder S., Ghoshal K., Kutay H., Datta J., Roy S., Lucas D.M., Jacob S.T. PTPROt inactivates the oncogenic fusion protein BCR/Abl and suppresses transformation of K562 cells. J. Biol. Chem. 2009, 284:455-464.
15. Cong F., Spencer S., Cote J.F., Wu Y., Tremblay M.L., Lasky L.A., Goff S.P. Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation. Mol. Cell 2000, 6:1413-1423.
16. Romsicki Y., Kennedy B.P., Asante-Appiah E. Purification and characterization of T cell protein tyrosine phosphatase reveals significant functional homology to protein tyrosine phosphatase-1B. Arch. Biochem. Biophys. 2003, 414:40-50.
17. Bourdeau A., Dube N., Tremblay M.L. Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Curr. Opin. Cell Biol. 2005, 17:203-209.
18. Shields B.J., Court N.W., Hauser C., Bukczynska P.E., Tiganis T. Cell cycle-dependent regulation of SFK, JAK1 and STAT3 signalling by the protein tyrosine phosphatase TCPTP. Cell Cycle 2008, 7:3405-3416.
19. Mattila E., Marttila H., Sahlberg N., Kohonen P., Tahtinen S., Halonen P., Perala M., Ivaska J. Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase. BMC Cancer 2010, 10:7.
20. Radha V., Nambirajan S., Swarup G. Subcellular localization of a protein-tyrosine phosphatase: evidence for association with chromatin. Biochem. J. 1994, 299(Pt 1):41-47.
21. Gupta V., Swarup G. Evidence for a role of transmembrane protein p25 in localization of protein tyrosine phosphatase TC48 to the ER. J. Cell Sci. 2006, 119:1703-1714.
22. Kamatkar S., Radha V., Nambirajan S., Reddy R.S., Swarup G. Two splice variants of a tyrosine phosphatase differ in substrate specificity, DNA binding, and subcellular location. J. Biol. Chem. 1996, 271:26755-26761.
23. Radha V., Kamatkar S., Swarup G. Binding of a protein-tyrosine phosphatase to DNA through its carboxy-terminal noncatalytic domain. Biochemistry 1993, 32:2194-2201.
24. Mosinger B., Tillmann U., Westphal H., Tremblay M.L. Cloning and characterization of a mouse cDNA encoding a cytoplasmic protein-tyrosine-phosphatase. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:499-503.
25. You-Ten K.E., Muise E.S., Itie A., Michaliszyn E., Wagner J., Jothy S., Lapp W.S., Tremblay M.L. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. 1997, 186:683-693.
26. Galic S., Hauser C., Kahn B.B., Haj F.G., Neel B.G., Tonks N.K., Tiganis T. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol. Cell. Biol. 2005, 25:819-829.
27. Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A., Meng T.C., Tonks N.K., Tiganis T. Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP. Mol. Cell. Biol. 2003, 23:2096-2108.
28. Shimizu T., Miyakawa Y., Iwata S., Kuribara A., Tiganis T., Morimoto C., Ikeda Y., Kizaki M. A novel mechanism for Imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-Abl fusion protein. Exp. Hematol. 2004, 32:1057-1063.
29. Mitra A., Kalayarasan S., Gupta V., Radha V. TC-PTP dephosphorylates the guanine nucleotide exchange factor C3G (RapGEF1) and negatively regulates differentiation of human neuroblastoma cells. PLoS One 2011, 6:e23681.
30. Tiganis T., Bennett A.M., Ravichandran K.S., Tonks N.K. Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol. Cell. Biol. 1998, 18:1622-1634.
31. Flint A.J., Tiganis T., Barford D., Tonks N.K. Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1680-1685.
32. Mitra A., Radha V. F-actin-binding domain of c-Abl regulates localized phosphorylation of C3G: role of C3G in c-Abl-mediated cell death. Oncogene 2010, 29:4528-4542.
33. Radha V., Rajanna A., Swarup G. Phosphorylated guanine nucleotide exchange factor C3G, induced by pervanadate and Src family kinases localizes to the Golgi and subcortical actin cytoskeleton. BMC Cell Biol. 2004, 5:31.
34. Radha V., Rajanna A., Mitra A., Rangaraj N., Swarup G. C3G is required for c-Abl-induced filopodia and its overexpression promotes filopodia formation. Exp. Cell Res. 2007, 313:2476-2492.
35. Shivakrupa R., Radha V., Sudhakar C., Swarup G. Physical and functional interaction between Hck tyrosine kinase and guanine nucleotide exchange factor C3G results in apoptosis, which is independent of C3G catalytic domain. J. Biol. Chem. 2003, 278:52188-52194.
36. Sriram G., Birge R.B. Emerging roles for CRK in human cancer. Genes Cancer 2010, 1:1132-1139.
37. Takino T., Tamura M., Miyamori H., Araki M., Matsumoto K., Sato H., Yamada K.M. Tyrosine phosphorylation of the CrkII adaptor protein modulates cell migration. J. Cell Sci. 2003, 116:3145-3155.
38. Kurzrock R., Talpaz M., Li L., Estrov Z. Distinct biological impact of dephosphorylation vs. downregulation of p210 BCR-Abl: implications for Imatinib mesylate response and resistance. Leuk. Lymphoma 2006, 47:1651-1664.
39. Lim Y.M., Wong S., Lau G., Witte O.N., Colicelli J. BCR/Abl inhibition by an escort/phosphatase fusion protein. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12233-12238.
40. Lu X., Chen J., Sasmono R.T., Hsi E.D., Sarosiek K.A., Tiganis T., Lossos I.S. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol. Cell. Biol. 2007, 27:2166-2179.
41. Kleppe M., Lahortiga I., El Chaar T., De Keersmaecker K., Mentens N., Graux C., Van Roosbroeck K., Ferrando A.A., Langerak A.W., Meijerink J.P., Sigaux F., Haferlach T., Wlodarska I., Vandenberghe P., Soulier J., Cools J. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 2010, 42:530-535.
42. Julien S.G., Dube N., Hardy S., Tremblay M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 2011, 11:35-49.
43. Shimizu T., Miyakawa Y., Oda A., Kizaki M., Ikeda Y. STI571-resistant KT-1 cells are sensitive to interferon-alpha accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1. Exp. Hematol. 2003, 31:601-608.
44. Birge R.B., Kalodimos C., Inagaki F., Tanaka S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun. Signal. 2009, 7:13.
45. Platanias L.C., Fish E.N. Signaling pathways activated by interferons. Exp. Hematol. 1999, 27:1583-1592.
46. LaMontagne K.R., Hannon G., Tonks N.K. Protein tyrosine phosphatase PTP1B suppresses p210 BCR-Abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14094-14099.
47. Echarri A., Pendergast A.M. Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway. Curr. Biol. 2001, 11:1759-1765.
48. Alvira D., Naughton R., Bhatt L., Tedesco S., Landry W.D., Cotter T.G. Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of BCR-Abl protein. J. Biol. Chem. 2011, 286:32313-32323.
49. Miething C., Mugler C., Grundler R., Hoepfl J., Bai R.Y., Peschel C., Duyster J. Phosphorylation of tyrosine 393 in the kinase domain of BCR-Abl influences the sensitivity towards Imatinib in vivo. Leukemia 2003, 17:1695-1699.
50. Backert S., Feller S.M., Wessler S. Emerging roles of Abl family tyrosine kinases in microbial pathogenesis. Trends Biochem. Sci. 2008, 33:80-90.
51. Shaul Y. c-Abl: activation and nuclear targets. Cell Death Differ. 2000, 7:10-16.